Goldman Sachs analyst Ziyi Chen upgraded Luye Pharma (LYPHF) to Neutral from Sell with a HK$3.13 price target The firm believes the downside risks have been largely reflected in the stock’s valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYPHF: